| Literature DB >> 28813659 |
Wen Pan1, Shu Zhu2, Kun Qu3, Katrina Meeth4, Jijun Cheng1, Kaixin He5, Hongdi Ma5, Yan Liao6, Xizhi Wen7, Christine Roden1, Zuzana Tobiasova8, Zheng Wei8, Jun Zhao8, Jun Liu1, Ji Zheng9, Bo Guo10, Sajid A Khan11, Marcus Bosenberg4, Richard A Flavell8, Jun Lu12.
Abstract
Ten-Eleven-Translocation-2 (Tet2) is a DNA methylcytosine dioxygenase that functions as a tumor suppressor in hematopoietic malignancies. We examined the role of Tet2 in tumor-tissue myeloid cells and found that Tet2 sustains the immunosuppressive function of these cells. We found that Tet2 expression is increased in intratumoral myeloid cells both in mouse models of melanoma and in melanoma patients and that this increased expression is dependent on an IL-1R-MyD88 pathway. Ablation of Tet2 in myeloid cells suppressed melanoma growth in vivo and shifted the immunosuppressive gene expression program in tumor-associated macrophages to a proinflammatory one, with a concomitant reduction of the immunosuppressive function. This resulted in increased numbers of effector T cells in the tumor, and T cell depletion abolished the reduced tumor growth observed upon myeloid-specific deletion of Tet2. Our findings reveal a non-cell-intrinsic, tumor-promoting function for Tet2 and suggest that Tet2 may present a therapeutic target for the treatment of non-hematologic malignancies.Entities:
Keywords: 5hmC; 5mC; Arg1; BMDM; HSC; Il1b; MDSC; TAM; Tet3; YUMM1.7
Mesh:
Substances:
Year: 2017 PMID: 28813659 PMCID: PMC5710009 DOI: 10.1016/j.immuni.2017.07.020
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745